alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.1**CERTIFICATION***Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities and Exchange Act of 1934,as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United StatesCode, V. Bryan Lawlis, Chief Executive Officer of Aradigm Corporation (the “Company”), and ThomasC. Chesterman, Chief Financial Officer of the Company, each hereby certifies that, to the best ofhis knowledge:1. The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2006, to which thisCertification is attached as Exhibit 32.1 (the “Quarterly Report”) fully complies with therequirements of Section 13(a) or Section 15(d) of the Exchange Act, and2. The information contained in the Quarterly Report fairly presents, in all material respects, thefinancial condition of the Company at the end of the period covered by the Quarterly Report andresults of operations of the Company for the period covered by the Quarterly Report.IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 14th day of August 2006.     /s/ Igor Gonda /s/ Thomas C. Chesterman   President and Chief Executive Officer  Senior Vice President and Chief Financial Officer       Dated: August 14, 2006 Dated: August 14, 2006   *This certification accompanies the Form 10-Q to which it relates, is not deemed filed with theSecurities and Exchange Commission and is not to be incorporated by reference into any filing ofAradigm Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of anygeneral incorporation language contained in such filing.
11 TH COURT OF APPEALS

EASTLAND

, TEXAS

JUDGMENT

Danny Eugene Ivie

, * From the 42nd District

Court of Taylor County,

Trial Court No. 24059A

.

Vs. No. 11

- 11

- 00122

- CR * April 18, 2013

The State of Texas, * Opinion by Willson, J.

(Panel consists of: Wright, C.J.,

McCall, J., and Willson , J. )

This court has inspected the record in this cause and concludes that there is no error in

the judgment below. Therefore, in accordance with this court ’ s opinion, the judgment of the

trial court is in all thin gs affirmed.
[Federal Register Volume 89, Number 182 (Thursday, September 19, 2024)]
[Notices]
[Page 76863]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21415]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Initial Review Group; Diabetes, Endocrinology 
and Metabolic Diseases B Study Section.
    Date: October 23-25, 2024.
    Time: 10:00 a.m. to 3:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, NIDDK, Democracy II, Suite 
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Charlene J. Repique, Ph.D., Scientific Review 
Officer, National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health, 6707 Democracy Boulevard, 
Rm 7347, Bethesda, MD 20892-5452, (301) 451-3638, 
<a href="/cdn-cgi/l/email-protection#64070c051608010a014a1601140d151101240a0d0c4a030b12"><span class="__cf_email__" data-cfemail="d3b0bbb2a1bfb6bdb6fda1b6a3baa2a6b693bdbabbfdb4bca5">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: September 15, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21415 Filed 9-18-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 32.2


                           CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


     I,  Mitchell  Binder, Chief Financial Officer of Orbit International Corp.,
certify,  pursuant to 18 U.S.C.   1350, as enacted by  906 of the Sarbanes-Oxley
Act  of  2002,  that:

     (1)     The  Annual  Report  on Form 10-K for the period ended December 31,
2008  (the "Annual Report") which this statement accompanies fully complies with
the  requirements  of  Section  13(a) or 15(d) of the Securities Exchange Act of
1934;  and

     (2)     information  contained in the Annual Report fairly presents, in all
material  respects,  the  financial condition and results of operations of Orbit
International  Corp.

Dated: March 31, 2009
                                   /s/ Mitchell Binder
                                   -------------------
                                   Mitchell Binder
                                   Chief Financial Officer

A  signed  original  of this written statement required by Section 906, or other
document  authenticating, acknowledging or otherwise adopting the signature that
appears  in  typed  form within the electronic version of this written statement
required by Section 906, has been provided to Orbit International Corp. and will
be  retained  by  Orbit  International Corp. and furnished to the Securities and
Exchange  Commission  or  its  staff  upon  request.
Exhibit 21

SUBSIDIARIES OF OSMONICS, INC.

|Percentage Ownership |  |                                        |  |                         
|-------------------- |  | -------------------------------------- |  | ------------------------
|100%                 |  | VAPONICS, INC.                         |  | A Massachusetts Corp.   
|100%                 |  | PORETICS CORPORATION                   |  | A Delaware Corporation  
|100%                 |  | OSMONICS ASIA/PACIFIC LTD.             |  | A Hong Kong Corporation 
|100%                 |  | OSMONICS EUROPA, S.A.                  |  | A Switzerland Corp.     
|100%                 |  | OZONE RESEARCH & EQUIPMENT CORP.       |  | An Arizona Corporation  
|100%                 |  | GHIA, INC.                             |  | A Nevada Corporation    
|100%                 |  | AUTOTROL CORPORATION                   |  | A Wisconsin Corporation 
|100%                 |  | NIPPON OSMONICS LTD.                   |  | A Japan Corporation     
|100%                 |  | AUTOTROL S.A.                          |  | A France Corporation    
|100%                 |  | OSMONICS INTL SALES CORP.              |  | A Virgin Islands Corp.  
|100%                 |  | MICROL SYSTEMS, LTD.                   |  | An England Corporation  
|100%                 |  | DESALINATION SYSTEMS, INC.             |  | A California Corp.      
|50%                  |  | NIPPON AUTOTROL K.K.                   |  | A Japan Corporation     
|100%                 |  | AQUAMATIC, INC.                        |  | A Delaware Corporation  
|100%                 |  | MEMBREX, INC.                          |  | A Delaware Corporation  
|100%                 |  | MICRON SEPARATIONS, INC.               |  | A New York Corporation  
|100%                 |  | MICRON SEPARATIONS INTERNATIONAL, INC. |  | A Virgin Islands Corp.  
|100%                 |  | ZYZATECH WATER SYSTEMS, INC.           |  | A Washington Corporation
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of the Treasury

###### Internal Revenue Service

# AGENCY:

Internal Revenue Service (IRS) Treasury.

# ACTION:

Notice of meeting.

# SUMMARY:

An open meeting of the Taxpayer Advocacy Panel's Tax Forms and Publications Project Committee will be conducted. The Taxpayer Advocacy Panel is soliciting public comments, ideas, and suggestions on improving customer service at the Internal Revenue Service. This meeting will be held via teleconference.

# DATES:

The meeting will be held Thursday, October 10, 2024.

# FOR FURTHER INFORMATION CONTACT:

Ann Tabat at 1-888-912-1227 or (602) 636-9143.

# SUPPLEMENTARY INFORMATION:

                    Notice is hereby given pursuant to section 10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. app. (1988) that a meeting of the Taxpayer Advocacy Panel's Tax Forms and Publications Project Committee will be held Thursday, October 10, 2024, at 2:30 p.m. eastern time. The public is invited to make oral comments or submit written statements for consideration. Due to limited time and structure of meeting, notification of intent to participate must be made with Ann Tabat. For more information, please contact Ann Tabat at 1-888-912-1227 or (602) 636-9143, or write TAP Office, 4041 N Central Ave., Phoenix, AZ 85012 or contact us at the website:                     *http://www.improveirs.org.*                     The agenda will include TAP 2024 committee project focus areas.                

Dated: September 9, 2024.

Shawn Collins,

Director, Taxpayer Advocacy Panel. 

[FR Doc. 2024-21045 Filed 9-16-24; 8:45 am]

BILLING CODE 4830-01-P
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998             DEC-31-1998
<PERIOD-START>                             JUL-01-1998             JAN-01-1998
<PERIOD-END>                               SEP-30-1998             SEP-30-1998
<CASH>                                           2,547                   2,547
<SECURITIES>                                     3,974                   3,974
<RECEIVABLES>                                    4,383                   4,383
<ALLOWANCES>                                   (1,419)                 (1,419)
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                                10,310                  10,310
<PP&E>                                           2,600                   2,600
<DEPRECIATION>                                 (1,804)                 (1,804)
<TOTAL-ASSETS>                                  11,106                  11,106
<CURRENT-LIABILITIES>                            4,628                   4,628
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                           118                     118
<OTHER-SE>                                       6,360                   6,360
<TOTAL-LIABILITY-AND-EQUITY>                    11,106                  11,106
<SALES>                                          1,874                   9,926
<TOTAL-REVENUES>                                 1,874                   9,926
<CGS>                                            2,346                   8,094
<TOTAL-COSTS>                                    2,346                   8,094
<OTHER-EXPENSES>                                 4,222                  11,805
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                               (109)                   (330)
<INCOME-PRETAX>                                (4,585)                 (9,643)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                            (4,585)                 (9,643)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                   (4,585)                 (9,643)
<EPS-PRIMARY>                                  ($0.39)                 ($0.83)
<EPS-DILUTED>                                  ($0.39)                 ($0.83)
        

</TABLE>
[Federal Register Volume 89, Number 182 (Thursday, September 19, 2024)]
[Notices]
[Page 76888]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21300]


-----------------------------------------------------------------------

POSTAL SERVICE


Product Change--Priority Mail Express, Priority Mail, and USPS 
Ground Advantage[supreg] Negotiated Service Agreement

AGENCY: Postal Service<SUP>TM</SUP>.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Postal Service gives notice of filing a request with the 
Postal Regulatory Commission to add a domestic shipping services 
contract to the list of Negotiated Service Agreements in the Mail 
Classification Schedule's Competitive Products List.

DATES: Date of required notice: September 19, 2024.

FOR FURTHER INFORMATION CONTACT: Sean C. Robinson, 202-268-8405.

SUPPLEMENTARY INFORMATION: The United States Postal Service[supreg] 
hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on 
September 3, 2024, it filed with the Postal Regulatory Commission a 
USPS Request to Add Priority Mail Express, Priority Mail & USPS Ground 
Advantage[supreg] Contract 287 to Competitive Product List. Documents 
are available at www.prc.gov, Docket Nos. MC2024-605, CP2024-613.

Sean C. Robinson,
Attorney, Corporate and Postal Business Law.
[FR Doc. 2024-21300 Filed 9-18-24; 8:45 am]
BILLING CODE 7710-12-P
|                                                |
|------------------------------------------------|
|                                                |  |  |
| Delaware                                       | 0-17948 | 94-2838567 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

----

|        |
|--------|
|        |  |
| o      | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|   |   |
| o      | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|   |   |
| o      | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|   |   |
| o      | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

----

|             |
|-------------|
|             |  |  |
| Exhibit No. |   | Description |
| 99.1        |   | Press release dated January 31, 2017, relating to Electronic Arts Inc.’s financial results for the fiscal quarter ended December 31, 2016. |

----

|        |
|--------|
|        |  |  |  |
|   |   |  ELECTRONIC ARTS INC. |
|   |   |   |   |
| Dated: | January 31, 2017 | By: | /s/ Blake Jorgensen |
|   |   |   | Blake Jorgensen |
|   |   |   | Executive Vice President, Chief Financial Officer |

----

|             |
|-------------|
|             |  |  |
| Exhibit No. |   | Description |
| 99.1        |   | Press release dated January 31, 2017, relating to Electronic Arts Inc.’s financial results for the fiscal quarter ended December 31, 2016. |
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RFA-DK-23-011: CKM for the Safe Use of SGLT2i in T1D.                    

*Date:*                         October 29, 2024.                    

*Time:*                         10:00 a.m. to 2:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Lan Tian, Ph.D., Scientific Review Officer, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 6707 Democracy Boulevard, Bethesda, MD 20892, (301) 496-7050,                         *lan.tian@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: September 15, 2024.

Miguelina Perez, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-21416 Filed 9-18-24; 8:45 am]

BILLING CODE 4140-01-P
JUDGMENT

Court of Appeals 

 

First District of Texas 

NO. 01-14-00458-CV

JAGDISH TUMMALA, M.D., EVEREST INPATIENT PHYSICIANS, PLLC, SHAH & 

DICHOSO, PLLC, PRAGNESH R. SHAH, M.D., P.A., AND DARYL D. DICHOSO, 

M.D., P.A., Appellants/Cross-Appellees

V.

TOTAL INPATIENT SERVICES, P.A., Appellee/Cross-Appellant

Appeal from the 270th District Court of Harris County. (Tr. Ct. No. 2012-72321).

This case is an appeal from the final judgment signed by the trial court on May 15, 

2014. After submitting the case on the appellate record and the arguments properly 

raised by the parties, the Court holds that there was reversible error in the portion of the 

trial court’s judgment as to liability and damages. Accordingly, the Court reverses the 

portion of the trial court’s judgment rendering judgment for appellee/cross-appellant, 

Total Inpatient Services, P.A., and against appellants/cross-appellees, Jagdish Tummala, 

M.D., Everest Inpatient Physicians, PLLC, Shah & Dichoso, PLLC, Pragnesh R. Shah, 

M.D., P.A., and Daryl Dichoso, M.D., P.A., and awarding Total Inpatient Services, P.A.

damages, post-judgment interest, and court costs. The Court further renders judgment 

that Total Inpatient Services, P.A. take nothing on its claims against appellants.
The Court further holds that there was no reversible error in the remaining 

portions of the trial court’s judgment. Therefore, the Court affirms the remaining 

portions of the trial court’s judgment.

The Court orders that the appellee, Total Inpatient Services, P.A., pay all appellate 

costs.

The Court orders that this decision be certified below for observance.

Judgment rendered August 27, 2015.

Panel consists of Justices Jennings, Higley, and Huddle. Opinion delivered by Justice 

Jennings.